W C Jackson1, K Suresh1, C Maurino1, M Feng2, K C Cuneo1, R K Ten Haken1, T S Lawrence1, M J Schipper1, D Owen3. 1. University of Michigan, Department of Radiation Oncology, United States. 2. University of California San Francisco, Department of Radiation Oncology, United States. 3. University of Michigan, Department of Radiation Oncology, United States. Electronic address: dawnowen@med.umich.edu.
Abstract
BACKGROUND AND PURPOSE: Patients with hepatocellular carcinoma (HCC) commonly have underlying liver dysfunction with variable tolerance to liver stereotactic body radiation therapy (SBRT). We hypothesized that insertion of a 1-month mid-treatment break would allow us to adapt treatment to the individual patient response, thereby reducing toxicity without compromising local control (LC). MATERIALS AND METHODS: We analyzed HCC patients receiving 3-5 fraction SBRT at our institution from 2005 to 2017. Over this time, patients were offered enrollment on prospective trials assessing individualized adaptive SBRT. Based on normal tissue complication probability and modeling of changes in liver function following a 1-month treatment break between fractions 3 and 4, patients could receive a total of 3 or 5 fractions. Patients not on trial received 3 or 5 fractions without a break. Toxicity was defined as a ≥2 point rise in Child-Pugh (CP) score within 6 months of SBRT. RESULTS: 178 patients were treated with SBRT to 263 HCCs. Median follow-up was 23 months. 86 treatments had a 1-month break. 1-Year LC was 95.4%; this was not different between patients treated with or without a break (p = 0.14). Controlling for tumor size and dose a break was not associated with inferior LC (HR: 0.58, 95%CI: 0.1-3.34, p = 0.54). 54 patients experienced a ≥2 point rise in CP score. Controlling for the number of prior liver directed therapies and mean liver dose, a treatment break reduced the odds of toxicity (OR: 0.42, 95% CI: 0.17-1.03, p = 0.06). CONCLUSION: A one-month mid-treatment break and reassessment may reduce the odds of treatment related toxicity without compromising LC.
BACKGROUND AND PURPOSE:Patients with hepatocellular carcinoma (HCC) commonly have underlying liver dysfunction with variable tolerance to liver stereotactic body radiation therapy (SBRT). We hypothesized that insertion of a 1-month mid-treatment break would allow us to adapt treatment to the individual patient response, thereby reducing toxicity without compromising local control (LC). MATERIALS AND METHODS: We analyzed HCC patients receiving 3-5 fraction SBRT at our institution from 2005 to 2017. Over this time, patients were offered enrollment on prospective trials assessing individualized adaptive SBRT. Based on normal tissue complication probability and modeling of changes in liver function following a 1-month treatment break between fractions 3 and 4, patients could receive a total of 3 or 5 fractions. Patients not on trial received 3 or 5 fractions without a break. Toxicity was defined as a ≥2 point rise in Child-Pugh (CP) score within 6 months of SBRT. RESULTS: 178 patients were treated with SBRT to 263 HCCs. Median follow-up was 23 months. 86 treatments had a 1-month break. 1-Year LC was 95.4%; this was not different between patients treated with or without a break (p = 0.14). Controlling for tumor size and dose a break was not associated with inferior LC (HR: 0.58, 95%CI: 0.1-3.34, p = 0.54). 54 patients experienced a ≥2 point rise in CP score. Controlling for the number of prior liver directed therapies and mean liver dose, a treatment break reduced the odds of toxicity (OR: 0.42, 95% CI: 0.17-1.03, p = 0.06). CONCLUSION: A one-month mid-treatment break and reassessment may reduce the odds of treatment related toxicity without compromising LC.
Authors: Jonathan Klein; Laura A Dawson; Haiyan Jiang; John Kim; Rob Dinniwell; James Brierley; Rebecca Wong; Gina Lockwood; Jolie Ringash Journal: Int J Radiat Oncol Biol Phys Date: 2015-09-01 Impact factor: 7.038
Authors: Foster D Lasley; Edward M Mannina; Cynthia S Johnson; Susan M Perkins; Sandra Althouse; Mary Maluccio; Paul Kwo; Higinia Cárdenes Journal: Pract Radiat Oncol Date: 2015-04-18
Authors: Shaelyn Culleton; Haiyan Jiang; Carol R Haddad; John Kim; Jim Brierley; Anthony Brade; Jolie Ringash; Laura A Dawson Journal: Radiother Oncol Date: 2014-06-03 Impact factor: 6.280
Authors: Philip J Johnson; Sarah Berhane; Chiaki Kagebayashi; Shinji Satomura; Mabel Teng; Helen L Reeves; James O'Beirne; Richard Fox; Anna Skowronska; Daniel Palmer; Winnie Yeo; Frankie Mo; Paul Lai; Mercedes Iñarrairaegui; Stephen L Chan; Bruno Sangro; Rebecca Miksad; Toshifumi Tada; Takashi Kumada; Hidenori Toyoda Journal: J Clin Oncol Date: 2014-12-15 Impact factor: 44.544
Authors: Laura A Dawson; Daniel Normolle; James M Balter; Cornelius J McGinn; Theodore S Lawrence; Randall K Ten Haken Journal: Int J Radiat Oncol Biol Phys Date: 2002-07-15 Impact factor: 7.038
Authors: Matthew J Schipper; Jeremy M G Taylor; Randy TenHaken; Martha M Matuzak; Feng-Ming Kong; Theodore S Lawrence Journal: Stat Med Date: 2014-08-27 Impact factor: 2.373
Authors: Kyle C Cuneo; Theresa Devasia; Yilun Sun; Matthew J Schipper; David Karnak; Mary A Davis; Dawn Owen; Mary Feng; Issam El Naqa; Latifa Bazzi; Randy Ten Haken; Theodore S Lawrence Journal: Transl Oncol Date: 2019-05-09 Impact factor: 4.243
Authors: Theodore S Hong; Clemens Grassberger; Beow Y Yeap; Wenqing Jiang; Jennifer Y Wo; Lipika Goyal; Jeffrey W Clark; Christopher H Crane; Eugene J Koay; Simona Dima; Christine E Eyler; Irinel Popescu; Thomas F DeLaney; Andrew X Zhu; Dan G Duda Journal: NPJ Precis Oncol Date: 2018-10-18
Authors: Mishal Mendiratta-Lala; Anum Aslam; Katherine E Maturen; Maria Westerhoff; Chris Maurino; Neehar D Parikh; Yilun Sun; Christopher J Sonnenday; Erica B Stein; Kimberly L Shampain; Ravi K Kaza; Kyle Cuneo; William Masch; Richard Kinh Gian Do; Theodore S Lawrence; Dawn Owen Journal: Int J Radiat Oncol Biol Phys Date: 2021-10-10 Impact factor: 8.013